Clinical trials: Inhalation
Asthma
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
The primary objective of this study is to evaluate the dose response, efficacy, and safety of 4 different doses of salmeterol Spiromax (6.25, 12.5, 25, and 50 mcg) each combined with a fixed dose of fluticasone propionate (100…
- Trial name
- NCT01772368
- Testing
- Fp MDPI, FS MDPI, Advair Diskus
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pulmonary Disease, Chronic Obstructive
A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD
This is a 24-week, phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The study will have 9 scheduled visits and a telephone contact Follow-up visit one week following the end of study…
- Trial name
- NCT01636713
- Testing
- GSK573719/VI 62.5/25, GSK573719/VI 125/25
- Where
- 44 sites in China, Philippines and 3 more
- Volunteers
- 581 people
- Sponsor
- GlaxoSmithKline
Oropharyngeal Dysphagia, Oropharyngeal Cancer
Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer
Cancers of the head and neck require surgical, radiation, and chemotherapy treatments that are intended to cure the disease. These treatments have toxic effects on muscles and structures that are necessary to swallow safely and…
- Trial name
- RSPT (NCT01032928)
- Testing
- Respiratory-Swallow Phase training
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- US Department of Veterans Affairs
Asthma
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller…
- Trial name
- PONENTE (NCT03557307)
- Testing
- Benralizumab
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Cystic Fibrosis
Self-dispersing Liquids as Aerosol Drug Carriers
Inhaled medications are often used to treat lung diseases such as cystic fibrosis. We are performing this study to determine whether inhaled medications dissolved in surfactant-based solutions will distribute more evenly…
- Trial name
- NCT00628134
- Testing
- calfactant, isotonic saline
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pittsburgh
Inhalational Anthrax
Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin
- Trial name
- NCT01952444
- Testing
- ETI-204, Ciprofloxacin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Elusys Therapeutics
Prematurity, Bronchopulmonary Dysplasia
Inhaled Nitric Oxide and Neuroprotection in Premature Infants
The purpose of this study is to determine whether inhaled nitric oxide improves the neurological outcome for premature infants.
- Conditions
- Prematurity, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia
- Trial name
- NOVA2 (NCT00515281)
- Testing
- inhaled nitric oxide, oxygen
- Where
- United States
- Volunteers
- 273 people
- Sponsor
- University of Chicago
Chronic Obstructive Pulmonary Disease
Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
To evaluate the efficacy and safety of arformoterol tartrate inhalation solution 30μg/4mL QD (two 15μg/2mL dosed in combination) over a 24-hour period compared to arformoterol tartrate inhalation solution 15μg/2 mL BID in…
- Trial name
- NCT00571428
- Testing
- Arformoterol Tartrate Inhalation Solution
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sumitomo Pharma America, Inc.
Type 2 Diabetes
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Insulin-naive subjects with Type 2 Diabetes Mellitus who are sub-optimally controlled on either maximum tolerated dose of metformin or maximum tolerated dose of metformin plus one or two other oral anti-diabetic medications will…
- Trial name
- NCT01451398
- Testing
- Technosphere® Insulin, Technosphere Powder
- Where
- 76 sites in United States, Brazil and 2 more
- Volunteers
- 353 people
- Sponsor
- Mannkind Corporation
Asthma
Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma
Specific Aim: To determine whether a prescription for Inhaled Corticosteroids (ICS) added to standard Emergency Department (ED) discharge therapy for young children with persistent asthma symptoms increases ICS use and improves…
- Trial name
- NCT00294398
- Testing
- ICS Prescription + Standard Asthma ED Discharge Therapy, Standard Asthma ED Discharge Therapy
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Children's Hospital of Philadelphia
Bronchiolitis
Inhaled Hypertonic Saline Use in the Emergency Department to Treat Acute Viral Bronchiolitis
Acute viral bronchiolitis is an extremely common childhood disease, responsible for approximately 17% of childhood admissions to hospital per year, with an annually cost that reaches U$ 500 million.
- Trial name
- NCT02045238
- Testing
- Hypertonic Saline, Chest X-Ray, Respiratory virus screening test
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- University of Sao Paulo
Insomnia, Sleep-Disordered Breathing
CPAP vs ASV for Insomnia
The study will determine which of two different types of positive airway pressure (PAP therapy) modes are more effective in reducing sleep breathing events in chronic insomnia patients and in decreasing insomnia severity.
- Trial name
- P2P (NCT02365064)
- Testing
- AirCurve 10 ASV
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- ResMed
Ventilators, Mechanical, Work of Breathing
Effort of Breathing Guided Ventilator Protocol
This pilot study tests the feasibility of using a computerized ventilator management protocol seeking to encourage lung protective ventilation during the acute phase of ventilation, and esophageal manometry based titration of…
- Trial name
- EOBvent (NCT02989246)
- Testing
- Ventilator protocol, Esophageal Catheter
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Children's Hospital Los Angeles
Asthma
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in…
- Trial name
- NCT02141854
- Testing
- FS MDPI, Fp MDPI, Albuterol/salmeterol HFA MDI
- Where
- 154 sites in United States, Canada and 7 more
- Volunteers
- 882 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA
The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.
- Trial name
- BORA (NCT02258542)
- Testing
- Benralizumab
- Where
- 429 sites in United States, Argentina and 22 more
- Volunteers
- 2,133 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting
A Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study"
- Trial name
- NCT00467896
- Testing
- Iloprost PD-6, Iloprost PD-15
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Actelion
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
This study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.
- Trial name
- SPEED (NCT00542880)
- Testing
- Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg, Seretide Diskus (salmeterol/fluticasone) 50/500 μg
- Where
- 59 sites in Argentina, Australia and 7 more
- Volunteers
- 442 people
- Sponsor
- AstraZeneca
Asthma
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests…
- Trial name
- NCT00441441
- Testing
- fluticasone propionate, fluticasone propionate/salmeterol
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.
This study will involve the use of a new compound, GW642444 that is being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00519376
- Testing
- GW642444M, GW642444H
- Where
- 4 sites in Germany
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline